| Identification | Back Directory | [Name]
BI-99179 | [CAS]
1291779-76-4 | [Synonyms]
BI-99179
BI-99179
(BI99179)
(1R,3S)-N-[4-(1,3-benzoxazol-2-yl)phenyl]-N-methyl-3-(propanoylamino)cyclopentane-1-carboxamide
Cyclopentanecarboxamide, N-[4-(2-benzoxazolyl)phenyl]-N-methyl-3-[(1-oxopropyl)amino]-, (1R,3S)- | [Molecular Formula]
C23H25N3O3 | [MDL Number]
MFCD25976795 | [MOL File]
1291779-76-4.mol | [Molecular Weight]
391.46 |
| Chemical Properties | Back Directory | [Boiling point ]
603.1±55.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
15.72±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats[1][2]. | [Biochem/physiol Actions]
BI 99179 is a non-cytotoxic (by LDH release; 30 μM, U937) orally available, brain-penetrant, highly potent and selective fatty acid synthase (FAS, FASN) inhibitor (IC50 = 79 nM by cell-free human FAS assay) with little or no inhibitory potency toward a panel of 30 receptors & channels (<20%>10 μM). BI 99179 inhibits cellular FAS activity in vitro (IC50 = 180 nM/human H1975, 600 nM/murine hypothalamic N-42 cells) and increases hypothalamic [malonyl-CoA] in rats in vivo (2 h post 10 mg/kg or 2-24 hr post 100 mg/kg p.o.). Note: adverse effects in rats are reported at day 4 (30 mg/kg) and day 9 (3 mg/kg). | [in vivo]
BI 99179 has a super pharmacokinetic profile in male Han/Wistar rats (oral application of 4 mg/kg) with half life (t1/2) of 3.0 h[1]. | [References]
[1] Kley JT, et al. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.Bioorg Med Chem Lett. 2011 Oct 1;21(19):5924-7. DOI:10.1016/j.bmcl.2011.07.083
[2] Prosanta K Singha, et al. Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells. Eur J Pharm Sci. 2020 Apr 7;149:105321. DOI:10.1016/j.ejps.2020.105321 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|